Inari Medical Q3 EPS Forecast Decreased by Leerink Partnrs

Inari Medical, Inc. (NASDAQ:NARI) – Research analysts at Leerink Partnrs lowered their Q3 2024 earnings estimates for shares of Inari Medical in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of ($0.13) for the quarter, down from their prior estimate of ($0.08). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.70) per share. Leerink Partnrs also issued estimates for Inari Medical’s Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.03) EPS and FY2026 earnings at $0.21 EPS.

Other equities analysts also recently issued reports about the company. Robert W. Baird decreased their price target on Inari Medical from $65.00 to $63.00 and set an “outperform” rating for the company in a research note on Wednesday, July 31st. Piper Sandler reiterated a “neutral” rating and issued a $50.00 price target on shares of Inari Medical in a report on Monday, August 26th. Stifel Nicolaus started coverage on Inari Medical in a research report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target on the stock. Canaccord Genuity Group lifted their price objective on shares of Inari Medical from $55.00 to $71.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical in a report on Friday, August 9th. They set a “buy” rating and a $68.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $57.44.

Inari Medical Trading Up 1.7 %

Shares of NASDAQ:NARI opened at $44.23 on Friday. The firm has a market cap of $2.57 billion, a PE ratio of -108.78 and a beta of 1.00. The company has a fifty day simple moving average of $44.20 and a 200 day simple moving average of $45.85. Inari Medical has a 12-month low of $36.73 and a 12-month high of $67.13.

Inari Medical (NASDAQ:NARI) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.25). Inari Medical had a negative net margin of 10.42% and a negative return on equity of 7.51%. The business had revenue of $145.82 million for the quarter, compared to analyst estimates of $143.96 million.

Hedge Funds Weigh In On Inari Medical

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in shares of Inari Medical by 6.9% in the fourth quarter. Vanguard Group Inc. now owns 5,038,292 shares of the company’s stock valued at $327,086,000 after acquiring an additional 325,586 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of Inari Medical by 462.4% during the 1st quarter. State of Alaska Department of Revenue now owns 31,095 shares of the company’s stock valued at $1,491,000 after purchasing an additional 25,566 shares during the period. Maryland State Retirement & Pension System acquired a new position in shares of Inari Medical during the 1st quarter valued at $886,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Inari Medical in the 1st quarter worth $30,000. Finally, Texas Permanent School Fund Corp lifted its holdings in shares of Inari Medical by 1.5% in the first quarter. Texas Permanent School Fund Corp now owns 44,858 shares of the company’s stock valued at $2,152,000 after buying an additional 664 shares during the period. Institutional investors and hedge funds own 90.98% of the company’s stock.

Insider Buying and Selling at Inari Medical

In other news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $55.23, for a total transaction of $165,690.00. Following the sale, the chief executive officer now owns 455,252 shares of the company’s stock, valued at approximately $25,143,567.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director William Hoffman sold 40,000 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the completion of the transaction, the director now owns 601,233 shares of the company’s stock, valued at approximately $27,067,509.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $55.23, for a total transaction of $165,690.00. Following the sale, the chief executive officer now owns 455,252 shares in the company, valued at approximately $25,143,567.96. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 91,000 shares of company stock valued at $4,175,030 in the last ninety days. Company insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.